Cardiff business receives equity from Finance Wales
AssayMetrics to commercialise prototype plate reader for use in the pharmaceutical and biotechnology industries
The early stage business has also received investment from a syndicate of business angels.
Dr Pierre Graves formed AssayMetrics in 2004. The following year, two senior scientists, Dr John Whateley and Dr Anthony Smith, joined the company.
In 2006 the company launched its chemical dye reagents, which are used in the biotechnology and pharmaceutical industries for compound screening. It subsequently developed its own Puretime novel fluorescent dye reagents before embarking on the development of a prototype plate reader, which added analytical instrumentation to its dye-based products.
According to AssayMetrics, a number of customers have expressed a wish to act as beta test sites for this plate reader.
‘The drug discovery market continues to grow despite the recession and we are delighted to be able to place a technology in the hands of customers that will make the process faster and more efficient,’ said Graves, chief executive of Assaymetrics.
Finance Wales provides commercial funding to small and medium-sized businesses throughout Wales, enabling them to realise their potential for innovation and growth.
A subsidiary of the Welsh Assembly Government, Finance Wales manages funds of more than £280m and has invested more than £157m in Wales-based businesses.
You may also like
Manufacturing
UK pharmaceutical manufacturers struggling to meet F-Gas compliance amid ageing cooling infrastructure
Read moreA new Aggreko report reveals that nearly all UK pharmaceutical manufacturers are facing barriers to upgrading cooling systems ahead of the accelerating F-Gas phase-down timeline
Trending Articles
You may also like
Research & Development
Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform
Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing
Manufacturing
Nemera partners with Therakind to expand nasal drug delivery portfolio with DriDose dry powder platform
The manufacturer has announced a strategic partnership with UK pharmaceutical company Therakind to advance the DriDose intranasal dry powder platform, adding dry powder delivery capabilities to complement Nemera's existing liquid nasal formulation offering